The IDH1-R132H mutation is a key factor in the biology and prognosis of gliomas, and it has been shown that patients with GBs with the IDH-1-R132H mutation exhibit improved outcomes compared with patients with wild-type IDH1 (22). This evidence concerns the gene IDH1 and Guillain-Barre syndrome.